纳武利尤单抗联合化疗一线治疗晚期胃食管腺癌的5年随访结果
CheckMate 649研究5年随访显示,在PD-L1 CPS≥5的晚期胃食管腺癌患者中,纳武利尤单抗联合化疗较单纯化疗持续改善总生存(HR 0.71,95%CI 0.61-0.81)和无进展生存(HR 0.71,95%CI 0.61-0.82),5年总生存率分别为16%和6%,安全性可控。
要点
- PD-L1 CPS≥5患者中,联合组5年总生存率为16%,化疗组为6%。
- 联合组客观缓解率为58%,化疗组为46%;中位缓解持续时间分别为8.5个月和6.9个月。
- 3/4级治疗相关不良事件发生率联合组为60%,化疗组为45%,未见新的安全性信号。
核心结论
- 纳武利尤单抗联合化疗在PD-L1阳性晚期胃食管腺癌一线治疗中持续显示长期生存获益和可接受的安全性,支持其作为标准治疗。
研究设计与样本
- CheckMate 649是一项随机对照试验,纳入既往未治疗、HER2阴性、不可切除的晚期或转移性胃食管腺癌成人患者,随机接受纳武利尤单抗联合化疗(n=789)或化疗(n=792)。
主要发现
- 在PD-L1 CPS≥5患者中,联合组与化疗组的总生存HR为0.71(95%CI 0.61-0.81),无进展生存HR为0.71(95%CI 0.61-0.82)。
- PD-L1 CPS≥5患者中,联合组与化疗组的5年总生存率分别为16%和6%,5年无进展生存率分别为10%和6%。
- 盲态独立中心评审的客观缓解率联合组为58%(95%CI 54%-62%),化疗组为46%(95%CI 42%-50%)。
- 中位缓解持续时间联合组为8.5个月(95%CI 7.7-9.9个月),化疗组为6.9个月(95%CI 5.9-7.6个月)。
- 生存和缓解获益在PD-L1 CPS≥1、PD-L1 CPS≥10及所有随机人群中同样维持。
关键数值与推荐
- PD-L1 CPS≥5患者中,联合组3/4级治疗相关不良事件发生率为60%,化疗组为45%。
临床怎么用
- 对于既往未治疗、HER2阴性、不可切除的晚期或转移性胃食管腺癌且PD-L1阳性的患者,可考虑纳武利尤单抗联合化疗作为一线标准治疗。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We report efficacy and safety results from the CheckMate 649 trial after 5 years of follow-up. PATIENTS AND METHODS: Adults with previously untreated, non-human epidermal growth factor receptor 2-positive, unresectable, advanced or metastatic gastroesophageal adenocarcinoma were randomized to receive nivolumab plus chemotherapy (n = 789) or chemotherapy (n = 792). Primary endpoints were met and reported previously, with nivolumab plus chemotherapy demonstrating superior overall survival (OS) and progression-free survival (PFS) versus chemotherapy in patients with programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥5. RESULTS: With a minimum follow-up of 60.1 months, the OS benefit [hazard ratio (HR) 0.71, 95% confidence interval (CI) 0.61-0.81] and PFS benefit (HR 0.71, 95% CI 0.61-0.82) with nivolumab plus chemotherapy versus chemotherapy in patients with PD-L1 CPS ≥5 were sustained. Five-year OS and PFS rates were 16% versus 6% and 10% versus 6%, respectively. Objective response rate per blinded independent central review was 58% (95% CI 54% to 62%) versus 46% (95% CI 42% to 50%), and median duration of response was 8.5 months (95% CI 7.7-9.9 months) versus 6.9 months (95% CI 5.9-7.6 months), respectively. Survival and response benefits were also maintained in patients with PD-L1 CPS ≥1, patients with PD-L1 CPS ≥10, and all randomized patients. Grade 3/4 treatment-related adverse events occurred in 60% of patients receiving nivolumab plus chemotherapy and 45% of patients receiving chemotherapy. No new safety concerns were observed. CONCLUSIONS: To our knowledge, these are the first reported 5-year results of a programmed cell death protein 1 inhibitor plus chemotherapy in gastroesophageal adenocarcinoma. Nivolumab plus chemotherapy continued to demonstrate long-term survival benefit and acceptable safety after 5 years of follow-up, reinforcing its use as a standard first-line treatment for PD-L1-positive patients.
引用
- Janjigian YY, Shitara K, Ajani JA, et al. Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649. Ann Oncol. 2026. PMID: 41687718. doi:10.1016/j.annonc.2026.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。